Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.

@article{Wlodawer1998InhibitorsOH,
  title={Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.},
  author={Alexander Wlodawer and Joanna R. Vondrasek},
  journal={Annual review of biophysics and biomolecular structure},
  year={1998},
  volume={27},
  pages={
          249-84
        }
}
  • Alexander Wlodawer, Joanna R. Vondrasek
  • Published 1998
  • Biology, Medicine
  • Annual review of biophysics and biomolecular structure
  • Retroviral protease (PR) from the human immunodeficiency virus type 1 (HIV-1) was identified over a decade ago as a potential target for structure-based drug design. This effort was very successful. Four drugs are already approved, and others are undergoing clinical trials. The techniques utilized in this remarkable example of structure-assisted drug design included crystallography, NMR, computational studies, and advanced chemical synthesis. The development of these drugs is discussed in… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 397 CITATIONS, ESTIMATED 51% COVERAGE

    Molecular Basis for Drug Resistance in HIV-1 Protease

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    1999
    2020

    CITATION STATISTICS

    • 15 Highly Influenced Citations

    • Averaged 15 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 165 REFERENCES

    Structural mechanisms of HIV drug resistance.

    VIEW 1 EXCERPT

    Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.

    VIEW 1 EXCERPT